Theravance Biopharma Inc
TBPHHealthcare|Biotechnology|USA
$16.94
-0.06 (-0.32%)
Tangible Book
$5.64
Graham Number
$11.62
Clinical Trials (74)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07133880 Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators | COPD (Chronic Obstructive Pulmonary Disease) | P4 | Recruiting | 72 | RCT, Double-blind | umeclidinium 62.5 µg and vilanterol 25 µg, Revefenacin 175 µg, Formoterol 20 µg, Placebo ( Revefenacin and Formoterol ), Placebo DPI |
| NCT05696717 Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy | Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | P3 | Active | 102 | RCT, Double-blind | Ampreloxetine, Placebo |
| NCT05165485 Phase 4 COPD and Suboptimal Inspiratory Flow Rate | Chronic Obstructive Pulmonary Disease | P4 | Completed | 404 | RCT, Double-blind | Revefenacin, Tiotropium, Revefenacin Placebo, Tiotropium Placebo |
| NCT02392208 Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5 | End-Stage Renal Disease, Stage 5 Chronic Kidney Disease | P4 | Completed | 8 | Open-label | Telavancin |
| NCT03095456 Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD | Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate (PIFR) | P3 | Completed | 207 | RCT, Double-blind | Revefenacin, Placebo for Revefenacin, Placebo for Spiriva Handihaler® |
| NCT02518139 A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Pulmonary Disease (COPD) | P3 | Completed | 1,060 | RCT, Double-blind | TD-4208, Tiotropium |
| NCT02459080 Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Pulmonary Disease (COPD) | P3 | Completed | 619 | RCT, Double-blind | TD-4208, Placebo |
| NCT02512510 Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Pulmonary Disease (COPD) | P3 | Completed | 611 | RCT, Double-blind | TD-4208, Placebo |
| NCT03573817 A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD | Chronic Obstructive Pulmonary Disease (COPD) | P3 | Completed | 122 | RCT, Double-blind | Revefenacin, Placebo, Formoterol |
| NCT03758443 Efficacy & Safety of TD-1473 in Ulcerative Colitis | Ulcerative Colitis (UC) | P2P3 | Terminated | 239 | RCT, Double-blind | TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C, Placebo |
| NCT04095793 Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure | Symptomatic Neurogenic Orthostatic Hypotension | P3 | Terminated | 110 | Open-label | ampreloxetine |
| NCT03750552 Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure | Symptomatic Neurogenic Orthostatic Hypotension | P3 | Completed | 195 | RCT, Double-blind | ampreloxetine, Placebo |
| NCT03920254 TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study | Ulcerative Colitis (UC) | P2P3 | Terminated | 46 | Double-blind | TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C |
| NCT03829657 Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure | Symptomatic Neurogenic Orthostatic Hypotension, MSA | P3 | Terminated | 203 | RCT, Double-blind | ampreloxetine, Placebo |
| NCT04315558 Revefenacin in Acute Respiratory Insufficiency in COPD | COPD, Acute Respiratory Failure | P2 | Completed | 21 | RCT, Double-blind | Revefenacin Inhalation Solution [Yupelri], Ipratropium Bromide |
| NCT01704404 7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease | COPD | P2 | Completed | 62 | RCT, Double-blind | TD-4208, Placebo |
| NCT02040792 A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) | COPD | P2 | Completed | 355 | RCT, Double-blind | TD-4208, Placebo |
| NCT02109172 A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Pulmonary Disease, COPD | P2 | Completed | 64 | RCT, Double-blind | TD-4208, Placebo |
| NCT03064113 Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Pulmonary Disease, COPD | P2 | Completed | 32 | RCT, Double-blind | Placebo, TD-4208 700 μg, TD-4208 350 μg, Ipratropium 500 μg |
| NCT01401985 A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC) | Opioid Induced Constipation | P2 | Completed | 95 | Single-blind | TD-1211, Placebo |
| NCT04402866 TD-0903 for ALI Associated With COVID-19 | Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19 | P2 | Completed | 235 | RCT, Double-blind | TD-0903, Placebo |
| NCT01718938 Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis | Gastroparesis | P2 | Completed | 34 | RCT, Double-blind | velusetrag dose 1, velusetrag dose 2, velusetrag dose 3, placebo |
| NCT01321879 Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients | Infection, Bacteremia | P2 | Completed | 40 | Open-label | Telavancin |
| NCT00674817 An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs. | Pulmonary Disease, Chronic Obstructive | P2 | Completed | 45 | RCT, Double-blind | 400 microgrammes GSK961081, 1200 microgrammes GSK961081 |
| NCT01458340 A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) | Attention-Deficit/Hyperactivity Disorder, ADHD | P2 | Completed | 295 | RCT, Double-blind | TD-9855, TD-9855, Placebo |
| NCT03635112 Efficacy and Safety of TD-1473 in Crohn's Disease | Crohn's Disease | P2 | Terminated | 167 | RCT, Double-blind | Placebo, TD-1473 |
| NCT02267525 The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study | Gastroparesis | P2 | Completed | 233 | RCT, Double-blind | Velusetrag, Placebo |
| NCT04150341 Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response | Asthma | P2 | Completed | 24 | RCT, Double-blind | TD-8236, Placebo |
| NCT00442832 TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection | Staphylococcal Skin Infection | P2 | Completed | 203 | RCT, Double-blind | TD-1792, Vancomycin |
| NCT01333540 A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation | Opioid-induced Constipation (OIC) | P2 | Completed | 69 | RCT, Double-blind | TD-1211, Placebo |
| NCT01953081 A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance | Enteral Feeding Intolerance | P1P2 | Completed | 13 | RCT, Double-blind | TD-8954, Metoclopramide |
| NCT02705755 TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) | Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension | P2 | Completed | 34 | RCT, Single-blind | TD-9855, Placebo |
| NCT01459926 A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation | Opioid Induced Constipation | P2 | Completed | 217 | RCT, Double-blind | TD-1211, TD-1211, TD-1211, Placebo |
| NCT01693692 Phase 2 Study of TD-9855 to Treat Fibromyalgia | Fibromyalgia | P2 | Completed | 392 | RCT, Double-blind | TD-9855 Group 1, TD-9855 Group 2, Placebo |
| NCT00391820 Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial) | Chronic Constipation | P2 | Completed | 360 | RCT, Double-blind | TD-5108 |
| NCT01040637 A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation | Healthy, Opioid-induced Constipation | P1P2 | Completed | 102 | RCT, Double-blind | TD-1211, TD-1211, TD-1211, TD-1211, TD-1211, TD-1211, TD-1211, TD-1211, TD-1211, Placebo |
| NCT02581592 Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment | Hepatic Impairment | P1 | Completed | 16 | Open-label | TD-4208 |
| NCT02772159 TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects | Chronic Obstructive Pulmonary Disease (COPD) | P1 | Completed | 9 | Open-label | TD-4208 |
| NCT02820311 Thorough QT (TQT) Study of TD-4208 in Healthy Subjects | Cardiac Repolarization in Healthy Subjects | P1 | Completed | 48 | RCT, Double-blind | TD-4208 175 mcg, TD-4208 700 mcg, Placebo for TD-4208, Moxifloxacin 400 mg |
| NCT02578082 Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment | Renal Impairment | P1 | Completed | 16 | Open-label | TD-4208 |
| NCT02657122 SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects | Healthy | P1 | Completed | 72 | RCT, Double-blind | TD-1473 for SAD, Placebo for SAD, TD-1473 for MAD, Placebo for MAD |
| NCT00887406 Study of GSK961081 in Healthy Volunteer Subjects | Pulmonary Disease, Chronic Obstructive | P1 | Completed | 46 | RCT, Double-blind | GSK961081 15mcg SD, GSK961081 3mcg SD, GSK961081 50mcg SD, Placebo SD, GSK961081 100mcg SD, GSK961081 200mcg SD, GSK961081 300mcg SD, GSK961081 100mcg RD, GSK961081 300mcg RD, Placebo RD |
| NCT02116543 TD-6450 MAD Study in HCV Infected Subjects | Hepatitis C, HCV | P1 | Completed | 47 | RCT, Double-blind | TD-6450, Placebo |
| NCT01655771 TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects | Constipation | P1 | Completed | 47 | Open-label | TD-1211 Dose 1, TD-1211 Dose 2 |
| NCT01949103 TD-1607 MAD Study in Healthy Subjects | Infections, Bacterial Infections | P1 | Completed | 48 | RCT, Double-blind | TD-1607, Placebo |
| NCT03652038 Single and Multiple Ascending Dose Study of TD-8236 by Inhalation | Asthma | P1 | Completed | 94 | RCT, Double-blind | TD-8236, Placebo |
| NCT01791049 TD-1607 SAD Study in Healthy Subjects | Serious Infections Due to Known or Suspected Gram-positive Pathogens | P1 | Completed | 64 | RCT, Double-blind | TD-1607, Placebo |
| NCT02903095 Single Ascending Dose Study of TD-1439 in Healthy Subjects | Healthy Subjects | P1 | Completed | 66 | RCT, Double-blind | TD-1439, Placebo |
| NCT00687700 A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy Volunteers | Pulmonary Disease, Chronic Obstructive | P1 | Completed | 23 | RCT | GSK961081, GSK961081 matching placebo, Propranolol, Propranolol matching placebo |
| NCT01568411 A Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD-1211 | Healthy | P1 | Completed | 20 | Open-label | TD-1211, TD-1211+ itraconazole |
| NCT02753855 Pharmacokinetics of Telavancin in Normal and Obese Subjects | Healthy | P1 | Completed | 32 | Open-label | Telavancin |
| NCT01644240 A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects | Gastrointestinal Motility Disorder | P1 | Terminated | 16 | RCT, Double-blind | TD-8954, Placebo - saline |
| NCT03555617 Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study | Inflammatory Bowel Disease | P1 | Completed | 36 | RCT, Open-label | TD-1473, Itraconazole |
| NCT01467726 Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects | Alzheimer's Disease | P1 | Completed | 40 | RCT, Double-blind | Velusetrag, Velusetrag, Placebo |
| NCT05091723 TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation | Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19) | P1 | Completed | 14 | Open-label | Nezulcitinib (TD-0903) Dose A, Nezulcitinib (TD-0903) Dose B |
| NCT04587713 Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects | Intestinal Disorder, Bowel Diseases, Inflammatory | P1 | Completed | 58 | RCT, Open-label | TD-1473 [Tablet A], TD-1473 [Tablet B] |
| NCT02709928 Multiple Ascending Dose Study of TD-0714 in Healthy and Elderly Subjects | Healthy Adults, Elderly Subjects | P1 | Completed | 50 | RCT, Double-blind | TD-0714, Placebo |
| NCT02954263 Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects | Healthy Adults, Elderly Subjects | P1 | Completed | 40 | RCT, Double-blind | TD-1439, Placebo |
| NCT04688632 Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects | Symptomatic Neurogenic Orthostatic Hypertension, nOH | P1 | Completed | 72 | RCT, Double-blind | Ampreloxetine <Dose A>, Ampreloxetine <Dose B>, Ampreloxetine Placebo, Moxifloxacin, Moxifloxacin Placebo |
| NCT04200573 Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855 | Symptomatic Neurogenic Orthostatic Hypertension, nOH | P1 | Completed | 31 | Open-label | Ampreloxetine |
| NCT04589260 TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis (IPF) | P1 | Terminated | 72 | RCT, Double-blind | TD-1058, Placebo |
| NCT01924143 TD-9855 Mass Balance Study | ADHD, Fibromyalgia | P1 | Completed | 6 | Open-label | TD-9855 |
| NCT02663089 A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy Subjects | Pulmonary Disease, Chronic Obstructive | P1 | Completed | 6 | Open-label | [14C]-GSK961081 solution for IV infusion, [14C]-GSK961081 oral solution, GSK961081 dry powder for inhalation |
| NCT04350736 First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19 | Acute Lung Injury (ALI) Associated With COVID-19, Inflammatory Lung Conditions Associated With COVID-19 | P1 | Completed | 54 | RCT, Double-blind | TD-0903, Placebo |
| NCT02639078 Single Ascending Dose Study of TD-0714 in Healthy Subjects | Healthy | P1 | Completed | 56 | RCT, Double-blind | TD-0714, Placebo Comparator |
| NCT03103412 TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC) | Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects | P1 | Completed | 32 | RCT, Double-blind | TD-3504, 15N2-tofacitinib, Placebo |
| NCT02818686 TD-1473 for Active Ulcerative Colitis (UC) | Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe | P1 | Completed | 40 | RCT, Double-blind | TD-1473, Placebo |
| NCT02022306 TD-6450 SAD and MAD in Healthy Subjects | Hepatitis C | P1 | Completed | 111 | RCT, Double-blind | TD-6450, Placebo |
| NCT03432793 Drug-Drug Interaction (DDI) Study for TD-9855 | Drug Drug Interaction (DDI) | P1 | Completed | 41 | Open-label | TD-9855, Fluvoxamine, Itraconazole, Caffeine |
| NCT00550225 Succinate Salt Version of GSK961081 for Healthy Volunteers | Pulmonary Disease, Chronic Obstructive | P1 | Completed | 18 | RCT | GSK961081, GSK961081 matching placebo |
| NCT03408470 TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects | Intestinal Disorders, Bowel Diseases, Inflammatory | P1 | Completed | 20 | RCT, Open-label | TD-1473 oral capsule, [14C]-TD-1473 IV bolus, [14C]-TD-1473 Oral Capsule |
| NCT03750565 Multiple Dose Ethnobridging PK Study in Healthy Subjects | Inflammatory Bowel Diseases, IBD | P1 | Completed | 60 | RCT, Double-blind | TD-1473 - Dose A, TD-1473 - Dose B, TD-1473 - Dose C, Placebo |
| NCT04044339 Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects | Healthy | P1 | Completed | 56 | RCT, Double-blind | TD-5202, Placebo |
| NCT04681079 Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19 | COVID-19 | Completed | 14 | — | albuterol sulfate (MDI), albuterol sulfate (nebulizer) |